NICM
ROIV icon

Neo Ivy Capital Management’s Roivant Sciences ROIV Stock Holding History

Neo Ivy Capital Management’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-64,106
Closed -$1.78M – 475
2026
Q1 		$1.78M Sell
64,106
-277,248
-81% -$7.12M 0.47% 83
2025
Q4 		$7.41M Buy
341,354
+103,962
+44% +$2.05M 1.17% 4
2025
Q3 		$3.59M Buy
237,392
+165,362
+230% +$2.05M 0.88% 18
2025
Q2 		$812K Buy
+72,030
New +$781K 0.26% 135

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Neo Ivy Capital Management's ROIV Position: Q2 2026 in Review

Neo Ivy Capital Management sold out of Roivant Sciences (ROIV) in Q2 2026, closing a stake of 64,106 shares — an estimated $1.78M sold.

Neo Ivy Capital Management first reported a position in ROIV in Q2 2025 and held it in 4 quarters. The position peaked at $7.41M in Q4 2025. 500 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • Neo Ivy Capital Management reported no remaining Roivant Sciences position as of Q2 2026 after selling out during the quarter.
  • Neo Ivy Capital Management sold 64,106 Roivant Sciences shares in Q2 2026, an estimated $1.78M.
  • Neo Ivy Capital Management first reported a position in Roivant Sciences in Q2 2025 and held it in 4 quarters.
  • Neo Ivy Capital Management's Roivant Sciences position peaked at $7.41M in Q4 2025.
  • 500 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Neo Ivy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.